Johnson & Johnson (JNJ) 107.56 $JNJ
Final Glance: Medical Devices companies
AP - 29 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
Final Glance: Pharmaceuticals companies
AP - 29 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Sanofi's Priftin Gains U.S. Approval for Latent TB Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 47 mins ago
Sanofi (SNY) announced that Priftin was approved in the U.S. for another indication.
AGN: 213.71 (+1.74), JNJ: 107.56 (-0.16), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - 2 hrs 34 mins ago
MMLP: 33.46 (-0.74), HCP: 45.57 (+0.11), CAG: 36.51 (-0.14), PFE: 31.67 (-0.08), ED: 64.07 (+0.14), BBEP: 11.00 (-0.86), O: 46.16 (-0.12), BMY: 58.89 (-0.14), DRI: 57.85 (-0.26), T: 33.91 (-0.09), STON: 26.67 (-0.20), JNJ: 107.56 (-0.16), CBRL: 128.78 (+0.07), SUI: 58.55 (+0.14), S: 4.86 (+0.17), OHI: 38.42 (+0.15), FUN: 46.02 (-0.12), LINE: 17.05 (-1.20), EPR: 56.75 (+0.43), VZ: 48.78 (-0.01)
Midday Glance: Pharmaceuticals companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Midday Glance: Medical Devices companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
Stryker (SYK) Rewards Shareholders with 13% Dividend Hike - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 11:30AM CST
Major orthopedic device manufacturer, Stryker Corp. (SYK), recently hiked its quarterly dividend by 13% to 34.5 cents per share from 30.5 cents.
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), STJ: 69.33 (+0.17), SYK: 94.38 (-0.13)
Early Glance: Pharmaceuticals companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Early Glance: Medical Devices companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
GTCR Completes Sale of Devicor Medical Products
Business Wire - Thu Dec 04, 8:28AM CST
GTCR, a leading private equity firm, announced today it has completed the previously announced sale of its portfolio company, Devicor Medical Products ("Devicor" or the "Company"
, to Danaher Corporation's (NYSE: DHR) Leica Biosystems, a leading provider of anatomical pathology solutions and automation used to advance cancer diagnostics.
JNJ: 107.56 (-0.16), DHR: 84.58 (-0.27)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52)
Phase 1 underway for Ebola booster vaccine regimen
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:23AM CST
JNJ: 107.56 (-0.16), MRK: 60.92 (+0.34), NLNK: 36.44 (-1.49), GSK: 45.89 (-0.82)
Johnson & Johnson Bought Alios for Hepatitis C
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 7:21AM CST
Don't look now, but Johnson & Johnson last month bought up South San Francisco-based Alios BioPharma for a cool $1.75 billion . So what's afoot? What is the health care giant really after with this deal? Alios is a clinical stage...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94)
MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts
M2 - Thu Dec 04, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b8djj/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the South America Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in South America Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biomedica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/8b...int_aortic
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), EVAR: 6.78 (+0.03), LMAT: 7.36 (unch)
MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts
M2 - Thu Dec 04, 3:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxpfd4/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the APAC Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the APAC Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura - Aptus - B. Braun - Bolton - Braile Biomedica - Cardiatis - Cook - Endologix - Getinge - Gore - Grikin Advanced Materials - Johnson & Johnson's - Jotec - LeMaitre Vascular - Lifetech - Lombard - Medtronic - MicroPort Scientific - Nano Endoluminal - Terumo - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material For more information visit http://www.researchandmarkets.com/research/fx...int_aortic
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), LMAT: 7.36 (unch)
The Million-Dollar Retirement Portfolio: 6-Month Follow-Up
Dividend Math Guy - at Seeking Alpha - Wed Dec 03, 8:52PM CST
KMI: 41.46 (-0.37), CLX: 99.61 (+0.43), PNY: 38.09 (-0.07), BLK: 360.71 (+3.82), KMB: 114.60 (-0.10), LO: 63.90 (+0.01), KRFT: 59.70 (-0.49), SDRL: 12.33 (-0.98), O: 46.16 (-0.12), WEC: 50.30 (+0.37), VTR: 72.56 (+0.22), PEP: 97.75 (-0.57), SBUX: 81.31 (+0.84), T: 33.91 (-0.09), JNJ: 107.56 (-0.16), ETO: 25.98 (-0.15), V: 261.14 (-0.46), FAX: 5.70 (-0.04), HYH: 39.13 (+1.62), KO: 43.50 (-0.30), HCP: 45.57 (+0.11), NNN: 37.79 (+0.04), COP: 69.31 (-1.49), MO: 50.94 (-0.25), SO: 47.91 (+0.01), PM: 87.15 (-0.50), RDS.B: 70.21 (-1.00), MCD: 95.66 (+0.16), PG: 90.58 (+0.58), CVX: 112.28 (-1.43), VZ: 48.78 (-0.01), GIS: 53.00 (-0.04)
Johnson & Johnson
at Investor's Business Daily - Wed Dec 03, 5:40PM CST
Johnson & Johnson (JNJ) is looking into divesting its Splenda artificial sweetener, according to Reuters sources. The health care company has hired Goldman Sachs (GS) to help with sale plans. Splenda has annual revenue of about $300 mil. Johnson &...
JNJ: 107.56 (-0.16), GS: 191.95 (+1.00)
Third Quarter Earnings Season In Review: Sector Winners And Losers, The Misleading 'Record' Beat Rate And The Outlook For Q4
Leigh Drogen - Seeking Alpha - Wed Dec 03, 4:50PM CST
On Monday, the third quarter earnings season will officially close out, with H&R Block (NYSE: HRB ) as the final S&P 500 company to report. The season is ending with impressive earnings growth of 11.7%, paired with revenue growth of 4.8%,...
KO: 43.50 (-0.30), JNJ: 107.56 (-0.16), AA: 17.24 (+0.03), GE: 26.09 (-0.29), AZO: 588.07 (-2.48), NKE: 99.05 (+0.55), GILD: 101.82 (+0.94), MCD: 95.66 (+0.16), XOM: 94.37 (-0.58), DG: 67.79 (+1.10), PVH: 122.68 (-1.72), HRB: 34.14 (-0.33)
DexCom CEO Terry Gregg Explains 50% YTD Stock Leap, Plans for 2015
at The Street - Wed Dec 03, 3:54PM CST
DexCom shares are up over 50% for the year on four FDA approvals. CEO Terry Gregg says technology is driving its products to the forefront.
JNJ: 107.56 (-0.16), ABT: 45.49 (-0.19), PODD: 45.89 (-0.47), DXCM: 54.59 (+0.09), TNDM: 13.66 (-0.19), AAPL: 115.49 (-0.44)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 94.05 (+2.81), JNJ: 107.56 (-0.16), ENDP: 70.69 (-0.53), ACT: 267.50 (+1.66), DRRX: 0.89 (unch), NVS: 95.77 (+0.11), PTIE: 1.80 (-0.07)
Final Glance: Medical Devices companies
AP - 29 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
Final Glance: Pharmaceuticals companies
AP - 29 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Sanofi's Priftin Gains U.S. Approval for Latent TB Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 47 mins ago
Sanofi (SNY) announced that Priftin was approved in the U.S. for another indication.
AGN: 213.71 (+1.74), JNJ: 107.56 (-0.16), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36)
Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review
George Schneider - at Seeking Alpha - 2 hrs 34 mins ago
MMLP: 33.46 (-0.74), HCP: 45.57 (+0.11), CAG: 36.51 (-0.14), PFE: 31.67 (-0.08), ED: 64.07 (+0.14), BBEP: 11.00 (-0.86), O: 46.16 (-0.12), BMY: 58.89 (-0.14), DRI: 57.85 (-0.26), T: 33.91 (-0.09), STON: 26.67 (-0.20), JNJ: 107.56 (-0.16), CBRL: 128.78 (+0.07), SUI: 58.55 (+0.14), S: 4.86 (+0.17), OHI: 38.42 (+0.15), FUN: 46.02 (-0.12), LINE: 17.05 (-1.20), EPR: 56.75 (+0.43), VZ: 48.78 (-0.01)
Midday Glance: Pharmaceuticals companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Midday Glance: Medical Devices companies
AP - Thu Dec 04, 12:49PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
Stryker (SYK) Rewards Shareholders with 13% Dividend Hike - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 11:30AM CST
Major orthopedic device manufacturer, Stryker Corp. (SYK), recently hiked its quarterly dividend by 13% to 34.5 cents per share from 30.5 cents.
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), STJ: 69.33 (+0.17), SYK: 94.38 (-0.13)
Early Glance: Pharmaceuticals companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.56 (-0.16), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), BMY: 58.89 (-0.14)
Early Glance: Medical Devices companies
AP - Thu Dec 04, 10:07AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 113.96 (+0.31), JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), BAX: 73.57 (-0.16)
GTCR Completes Sale of Devicor Medical Products
Business Wire - Thu Dec 04, 8:28AM CST
GTCR, a leading private equity firm, announced today it has completed the previously announced sale of its portfolio company, Devicor Medical Products ("Devicor" or the "Company"
, to Danaher Corporation's (NYSE: DHR) Leica Biosystems, a leading provider of anatomical pathology solutions and automation used to advance cancer diagnostics. JNJ: 107.56 (-0.16), DHR: 84.58 (-0.27)
Why Biotech Stocks Don't Pay Dividends
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 04, 8:13AM CST
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don't have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52)
Phase 1 underway for Ebola booster vaccine regimen
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 7:23AM CST
JNJ: 107.56 (-0.16), MRK: 60.92 (+0.34), NLNK: 36.44 (-1.49), GSK: 45.89 (-0.82)
Johnson & Johnson Bought Alios for Hepatitis C
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 7:21AM CST
Don't look now, but Johnson & Johnson last month bought up South San Francisco-based Alios BioPharma for a cool $1.75 billion . So what's afoot? What is the health care giant really after with this deal? Alios is a clinical stage...
JNJ: 107.56 (-0.16), GILD: 101.82 (+0.94)
MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts
M2 - Thu Dec 04, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b8djj/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the South America Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in South America Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura Medical - Aptus Endosystems - B. Braun - Bolton Medical - Braile Biomedica - Cardiatis - Cook Medical - Endologix - Getinge Group - Gore Medical - Grikin Advanced Materials - Johnson & Johnson's Cordis Corporation - Jotec - LeMaitre Vascular - Lifetech Scientific - Lombard Medical - Medtronic - MicroPort Scientific Corporation - Nano Endoluminal - Terumo Corporation - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material Scitech For more information visit http://www.researchandmarkets.com/research/8b...int_aortic
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), EVAR: 6.78 (+0.03), LMAT: 7.36 (unch)
MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts
M2 - Thu Dec 04, 3:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxpfd4/medipoint_aortic) has announced the addition of the "MediPoint: Aortic Stent Grafts - APAC Analysis and Market Forecasts" report to their offering. Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Reasons to buy - Understand the trends shaping and driving the APAC Aortic Stent Grafts market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the APAC Aortic Stent Grafts market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. Key Topics Covered: 1 List of Tables 2 Introduction 3 Industry Overview 4 Unmet Needs 5 Market Opportunity Analysis 6 Market Drivers, Barriers, and Substitutes 7 Competitive Assessment 8 Pipeline Assessment 9 Clinical Trials to Watch 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned: - Altura - Aptus - B. Braun - Bolton - Braile Biomedica - Cardiatis - Cook - Endologix - Getinge - Gore - Grikin Advanced Materials - Johnson & Johnson's - Jotec - LeMaitre Vascular - Lifetech - Lombard - Medtronic - MicroPort Scientific - Nano Endoluminal - Terumo - TriVascular - Weike Medical Apparatus and Instrument - YTH Biological Material For more information visit http://www.researchandmarkets.com/research/fx...int_aortic
JNJ: 107.56 (-0.16), MDT: 73.94 (-0.90), LMAT: 7.36 (unch)
The Million-Dollar Retirement Portfolio: 6-Month Follow-Up
Dividend Math Guy - at Seeking Alpha - Wed Dec 03, 8:52PM CST
KMI: 41.46 (-0.37), CLX: 99.61 (+0.43), PNY: 38.09 (-0.07), BLK: 360.71 (+3.82), KMB: 114.60 (-0.10), LO: 63.90 (+0.01), KRFT: 59.70 (-0.49), SDRL: 12.33 (-0.98), O: 46.16 (-0.12), WEC: 50.30 (+0.37), VTR: 72.56 (+0.22), PEP: 97.75 (-0.57), SBUX: 81.31 (+0.84), T: 33.91 (-0.09), JNJ: 107.56 (-0.16), ETO: 25.98 (-0.15), V: 261.14 (-0.46), FAX: 5.70 (-0.04), HYH: 39.13 (+1.62), KO: 43.50 (-0.30), HCP: 45.57 (+0.11), NNN: 37.79 (+0.04), COP: 69.31 (-1.49), MO: 50.94 (-0.25), SO: 47.91 (+0.01), PM: 87.15 (-0.50), RDS.B: 70.21 (-1.00), MCD: 95.66 (+0.16), PG: 90.58 (+0.58), CVX: 112.28 (-1.43), VZ: 48.78 (-0.01), GIS: 53.00 (-0.04)
Johnson & Johnson
at Investor's Business Daily - Wed Dec 03, 5:40PM CST
Johnson & Johnson (JNJ) is looking into divesting its Splenda artificial sweetener, according to Reuters sources. The health care company has hired Goldman Sachs (GS) to help with sale plans. Splenda has annual revenue of about $300 mil. Johnson &...
JNJ: 107.56 (-0.16), GS: 191.95 (+1.00)
Third Quarter Earnings Season In Review: Sector Winners And Losers, The Misleading 'Record' Beat Rate And The Outlook For Q4
Leigh Drogen - Seeking Alpha - Wed Dec 03, 4:50PM CST
On Monday, the third quarter earnings season will officially close out, with H&R Block (NYSE: HRB ) as the final S&P 500 company to report. The season is ending with impressive earnings growth of 11.7%, paired with revenue growth of 4.8%,...
KO: 43.50 (-0.30), JNJ: 107.56 (-0.16), AA: 17.24 (+0.03), GE: 26.09 (-0.29), AZO: 588.07 (-2.48), NKE: 99.05 (+0.55), GILD: 101.82 (+0.94), MCD: 95.66 (+0.16), XOM: 94.37 (-0.58), DG: 67.79 (+1.10), PVH: 122.68 (-1.72), HRB: 34.14 (-0.33)
DexCom CEO Terry Gregg Explains 50% YTD Stock Leap, Plans for 2015
at The Street - Wed Dec 03, 3:54PM CST
DexCom shares are up over 50% for the year on four FDA approvals. CEO Terry Gregg says technology is driving its products to the forefront.
JNJ: 107.56 (-0.16), ABT: 45.49 (-0.19), PODD: 45.89 (-0.47), DXCM: 54.59 (+0.09), TNDM: 13.66 (-0.19), AAPL: 115.49 (-0.44)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 94.05 (+2.81), JNJ: 107.56 (-0.16), ENDP: 70.69 (-0.53), ACT: 267.50 (+1.66), DRRX: 0.89 (unch), NVS: 95.77 (+0.11), PTIE: 1.80 (-0.07)
